Induction of resectability of colorectal liver metastases (CLM) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) (POCHER trial)

被引：2
|
作者：
Garufi, C. [1 ]
Torsello, A. [1 ]
Tumolo, S. [2 ]
Mottolese, M. [1 ]
Melucci, E. [1 ]
Campanella, C. [1 ]
Zeuli, M. [1 ]
Sperduti, I. [1 ]
Ettorre, G. M. [3 ]
Cognetti, F. [1 ]
机构：
[1] Regina Elena Inst Canc Res, Rome, Italy
[2] Osped SM Angeli, Pordenone, Italy
[3] Osped S Camillo Roma, Rome, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71181-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：348 / 348
页数：1
相关论文
共 50 条
  • [21] A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma
    Gennatas, C.
    Papaxoinis, G.
    Michalaki, V.
    Mouratidou, D.
    Andreadis, Ch.
    Tsavaris, N.
    Pafiti, A.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (05) : 538 - 544
  • [22] A phase I study of CPT-11 plus chronomodulated (chrono) 5-Fluorouracil (5-FU) and L-folinic acid (FA) in advanced colorectal cancer (ACC) patients
    Garufi, C
    Tampellini, M
    D'Attino, RM
    Nistico, C
    Aschelter, AM
    Pugliese, P
    Caterino, M
    Giunta, S
    Faranda, A
    Tropea, F
    Comis, S
    Dogliotti, L
    Terzoli, E
    ANNALS OF ONCOLOGY, 1998, 9 : 37 - 37
  • [23] Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
    Van Cutsem, E
    Cunningham, D
    Huinink, WWT
    Punt, CJA
    Alexopoulos, CG
    Dirix, L
    Symann, M
    Blijham, GH
    Cholet, P
    Fillet, G
    Van Groeningen, C
    Vannetzel, JM
    Levi, F
    Panagos, G
    Unger, C
    Wils, J
    Cote, C
    Blanc, C
    Hérait, P
    Bleiberg, H
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (01) : 54 - 59
  • [24] Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU):: A phase II study
    Antón, A
    Aranda, E
    Carrato, A
    Marcuello, E
    Massutti, B
    Cervantes, A
    Abad, A
    Sastre, J
    Fenández-Martos, C
    Gallén, M
    Díaz-Rubio, E
    Huarte, L
    Balcells, M
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (08): : 639 - 643
  • [25] Pilot trial of 5-FU/oxaliplatin (CIFOX) for patients with metastatic colorectal cancer who progressed on 5-FU/LV/CPT-11 (IFL).
    Aparicio, A
    Iqbal, S
    Yang, D
    Groshen, S
    Park, D
    Garcia, A
    Lenz, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 312S - 312S
  • [26] BIMONTHLY CHEMOTHERAPY (CHT) WITH OXALIPLATIN (OHP), IRINOTECAN (CPT11), INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID (FU/FA) IN PATIENTS WITH METASTATIC COLORECTAL CANCER PRETREATED WITH CPT11-OR OHP-BASED CHT
    Nobili, S.
    Del Buono, S.
    Mazzocchi, V.
    Filippelli, F.
    Checcacci, D.
    Giglioni, B.
    Mazzei, T.
    Mini, E.
    ANNALS OF ONCOLOGY, 2004, 15 : 65 - 65
  • [27] A phase II study with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) in patients with metastatic colorectal cancer
    Destefanis, M
    Dalla Mola, A
    Ostellino, O
    Capello, C
    Milanesi, E
    Grillo, C
    Castiglione, F
    Venturino, A
    Porcile, G
    ANNALS OF ONCOLOGY, 2000, 11 : 67 - 67
  • [28] Cetuximab plus capecitabine (CAP) and oxaliplatin (LOHP) as salvage treatment for patients with metastatic colorectal cancer (CRC) relapsing after combination chemotherapy including oxaliplatin, irinotecan (CPT-11), and 5-fluorouracil (5-FU) or capecitabine
    Souglakos, J
    Androulakis, N
    Kalykaki, A
    Saridaki, Z
    Vardakis, N
    Kalbakis, K
    Agelaki, S
    Vamvakas, L
    Kentepozidis, N
    Giassas, S
    Mavroudis, D
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2005, 16 : 41 - 41
  • [29] A phase II experience with neoadjuvant irinotecan (CPT-II), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
    Bathe, Oliver F.
    Ernst, Scott
    Sutherland, Francis R.
    Dixon, Elijah
    Butts, Charles
    Bigam, David
    Holland, David
    Porter, Geoffrey A.
    Koppel, Jennifer
    Dowden, Scot
    BMC CANCER, 2009, 9
  • [30] Phase I study of CPT-11 and bolus 5-FU/l-leucovorin in patients with metastatic colorectal cancer
    Fujishima H.
    Kikuchi I.
    Miyanaga O.
    Ueda A.
    Baba E.
    Mitsugi K.
    Harada M.
    Nakano S.
    International Journal of Clinical Oncology, 2004, 9 (2) : 92 - 97
12345